BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240903
DTEND;VALUE=DATE:20240906
DTSTAMP:20260515T154455
CREATED:20240515T145207Z
LAST-MODIFIED:20240515T145207Z
UID:39128-1725321600-1725580799@www.pharmajournalist.com
SUMMARY:3rd Cell Therapy Analytical Development Summit Europe
DESCRIPTION:Bringing together technical experts\, the 3rd Cell Therapy Analytical Development Summit Europe\, is the definitive summit dedicated to defining and refining analytics to ensure the swift progression of highly efficacious products through IND/IMPD and clinical trials. \nConnect with industry-leaders like Achilles Therapeutics\, Avobis Bio\, Bristol Myers Squibb\, Johnson & Johnson\, GSK\, MHRA\, to advance the future development of potent\, safe and effective cell therapies! \nJoin us in London for 3 days of exclusive content focused on providing the exclusive technical insights needed to take your product from characterisation to validation and release! \nAccess the full session details today.
URL:http://www.pharmajournalist.com/event/3rd-cell-therapy-analytical-development-summit-europe/
LOCATION:15Hatfields\, Chadwick Court\, London\, SE1 8DJ\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240909
DTEND;VALUE=DATE:20240911
DTSTAMP:20260515T154455
CREATED:20240613T144451Z
LAST-MODIFIED:20240613T144520Z
UID:39254-1725840000-1726012799@www.pharmajournalist.com
SUMMARY:Wearable Injectors and Connected Devices USA
DESCRIPTION:The Wearable Injectors and Connected Devices event is the only conference that discusses both wearable injectors and connected devices in one event. Over two days\, we bring together executives within the pharmaceutical industry to discuss the opportunities and challenges that face on-body devices\, and to collaborate on the future of the industry. The event provides and intimate environment to speak with experts and peers to learn from each other’s experiences\, and to meet with a variety of solutions providers working to supplement the industry. \nThe experience: \n\nA collaborative environment for pharma\, biotech and device developers to discuss the latest trends and challenges within the wearable injectors and connected device market.\nLearn from key industry players about new technologies\, strategies and processes for the development of wearable injectors.\nGain insights into the regulatory processes for the approval of wearable injectors and develop a greater understanding of how-to bring devices to market.\nCreate a dialogue with industry leaders for wearable injectors\, and develop a network with the key stake-holders in the market.\nDelve into the world of digital health and connectivity for the healthcare sector\, and discuss the future of connectivity for wearables.\nExamine the importance of usability for at home injectors\, and what is needed to make a device appropriate for patient administration.\n\nWhy attend: \n\n2 full days of networking opportunities.\n16+ sessions with 75% of speakers from big pharma companies\nAn agenda designed for professionals within the wearable injectors space\, focused on the development\, implementation and application of wearable injectors and connected devices.\nThe only conference discussing wearable injectors and connected devices together.
URL:http://www.pharmajournalist.com/event/wearable-injectors-and-connected-devices-usa-2024/
LOCATION:Boston\, USA
ORGANIZER;CN="SAE Media Group":MAILTO:EVENTS@SAEMEDIAGROUP.COM
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240909
DTEND;VALUE=DATE:20240911
DTSTAMP:20260515T154455
CREATED:20240719T115013Z
LAST-MODIFIED:20240719T115144Z
UID:39420-1725840000-1726012799@www.pharmajournalist.com
SUMMARY:ADC & TRP Pharma & Biotech Partnering Summit
DESCRIPTION:Major moves in pharma and biotech partnering are reshaping the landscape. For ADC companies\, the challenge lies in standing out\, validating their offerings\, and securing clinical-ready assets amidst this whirlwind of activity. \nHow does one differentiate and obtain assets poised for clinical success in the next wave of deals? \nEnter the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit. \nVIEW THE FULL EVENT GUIDE \nWhy Attend? \n\nCuts through the noise of partnership events to gather a targeted critical mass of 100+ ADC companies\nProvides a platform for networking and fast-tracking the search and evaluation of earlier development assets\nEmpowers participants to navigate the complex partnering landscape with confidence by significantly improving the alignment\, efficiency\, and yield of conversations\n\nSecure your place here or get in touch with the team – info@hansonwade.com
URL:http://www.pharmajournalist.com/event/adc-trp-pharma-biotech-partnering-summit/
LOCATION:Revere Boston Common Hotel\, 200 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240911
DTEND;VALUE=DATE:20240913
DTSTAMP:20260515T154455
CREATED:20240613T153308Z
LAST-MODIFIED:20240613T153308Z
UID:39264-1726012800-1726185599@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes Connect
DESCRIPTION:SAE Media Group are proud to announce the inaugural Pre-Filled Syringes Connect event taking place on the 11th and 12th of September in Boston. As a new addition to SAE’s leading injectable drug delivery portfolio\, PFS Connect will bring together device thought-leaders from big pharma\, biotech and device developers in an intimate\, relaxed and engaging setting\, fostering collaborations and idea exchanges crucial for driving innovation in injectable drug delivery. \nThe two-day agenda will bring you a series of keynote presentations and roundtable discussions facilitated by industry experts sharing their invaluable expertise and experiences around industry challenges and emerging trends allowing you to come away equipped with actionable knowledge to enhance your device development initiatives and strategic approach. Keynote presentations will also give you the chance gain insight into the latest case studies and innovations in the field. We hope to welcome you to this must attend event in September 2024! \nFree to attend for Pharma and Biotechs.
URL:http://www.pharmajournalist.com/event/pre-filled-syringes-connect/
LOCATION:Boston\, USA
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240917
DTEND;VALUE=DATE:20240921
DTSTAMP:20260515T154455
CREATED:20240513T102940Z
LAST-MODIFIED:20240513T102940Z
UID:39084-1726531200-1726876799@www.pharmajournalist.com
SUMMARY:9th CAR-TCR Summit
DESCRIPTION:The commercial success of cell therapies is continuing to grow! With a recent TIL approval\, a shift to earlier line CAR-T treatment\, and further approvals set for this year\, 2024 will be pivotal to demonstrate the clinical benefit of cell therapies and advance breakthroughs in solid tumors and autoimmunity. \nThat’s why now’s the time to join the 9th CAR-TCR Summit: the industry’s definitive forum committed to progressing end-to-end cell therapy development. This year’s 2-day conference will accommodate in-depth tracks covering Discovery\, Translation\, Clinical Development\, Early-Stage Manufacturing\, Late-Stage Manufacturing\, Analytical Development and Supply Chain & Clinical Operations. \nThis is your team’s one-stop shop for all functions to discover cutting-edge innovations\, significant clinical data and gain insights into how to conquer the bottlenecks withholding optimal durability\, accessibility\, safety and cost-efficiency. \nJoin 130+ expert speakers and 1\,000+ cell therapy experts to collaborate to achieve the shared goal of delivering these curative treatments to the ever-growing population of patients in need. \nTo see the speaker faculty\, what’s new for 2024\, full session details\, who you will meet and much more\, view the full agenda now: https://ter.li/wjnrky
URL:http://www.pharmajournalist.com/event/9th-car-tcr-summit/
LOCATION:Hynes Convention Center\, 900 Boylston St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240917
DTEND;VALUE=DATE:20240920
DTSTAMP:20260515T154455
CREATED:20240515T095715Z
LAST-MODIFIED:20240515T095715Z
UID:39116-1726531200-1726790399@www.pharmajournalist.com
SUMMARY:2nd CRISPR-Based Therapy Analytical Development Summit
DESCRIPTION:Develop\, characterize\, and validate robust analytical tools that demonstrate safety\, efficacy\, and regulatory compliance of genome editing therapies \nAs CRISPR-based therapies become ever-complex\, drug developers urgently need to innovate the analytical tools available to effectively characterize their safety and efficacy profiles and agree upon gold standards moving forward. We are also witnessing increased regulatory scrutiny\, with the FDA closely studying off-target analysis conducted ahead of the approval of Casgevy\, before finalizing guidance on genome editing therapies in January. \nTo keep up with these growing analytical demands\, the 2nd CRISPR-Based Therapy Analytical Development Summit is returning to unite 50+ key figures across Analytical Development\, CMC & QC domains\, all with the common goal of developing more precise\, accurate\, and sensitive analytical assays. \nExpert discussions will highlight analytical innovation with both traditional and disruptive CRISPR-based therapies\, and span in vivo and ex vivo delivery\, covering the following core themes: \n\nCharacterization of guides\, nucleases\, and full drug constructs\nRobust non-clinical and CMC assay development\, including biodistribution studies\, potency assays\, and on-/off- target sequencing detection\, nomination\, and prediction\nMeeting regulatory expectations for analytical data to support IND submissions successfully\n\nIf you are working to develop\, characterize\, and validate more robust analytical tools to enable the progression of your early R&D work into a clinical therapy\, this is your collaborative forum to equip you with the latest innovation\, case studies\, and actionable insights to level up your analytical efforts.
URL:http://www.pharmajournalist.com/event/2nd-crispr-based-therapy-analytical-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240917
DTEND;VALUE=DATE:20240920
DTSTAMP:20260515T154455
CREATED:20240530T075911Z
LAST-MODIFIED:20240530T075911Z
UID:39192-1726531200-1726790399@www.pharmajournalist.com
SUMMARY:3rd mRNA Process Development & Manufacturing Summit
DESCRIPTION:Your Roadmap for mRNA Process Development & Manufacturing with Optimized Purification\, Process Analytics & Enhanced Formulation to Improve Cost-Effectiveness & Scalability into the Clinic & Beyond \nThe mRNA manufacturing industry is experiencing a wave of innovation with the development of cancer vaccines\, emerging therapeutics\, and novel gene editing tools. Yet\, significant challenges remain – largely around the speed\, cost of production\, and limited flexibility to improve current processes with new technologies. \nReturning to Boston this September\, the 3rd mRNA Process Development & Manufacturing Summit has been carefully put together to address the industry’s most prominent pain points. Hear from 30+ expert speakers from the likes of BioNTech\, Merck & Co.\, Moderna\, Nutcracker Therapeutics\, Pfizer\, Sanofi\, Strand Therapeutics and more across three days of content spanning two tracks dedicated to Research Scale and IND-Enabling & Clinical Scale process development. \nBoost your mRNA drug substance to drug product by implementing high throughput process development\, optimizing mRNA synthesis and purification\, speeding up process analytics and innovating formulation to unlock the unlimited potential of mRNA for all applications. \n\nDates: September 17-19\, 2024\nLocation: Westin Boston Seaport District\, Boston\, MA\nEvent Program: https://ter.li/k46oir\n\nNew for 2024\, join the mRNA Purification focus day to enhance your upstream and downstream purification processes\, or dive into 3 pre-conference workshops to harness high throughput process development technology\, master mRNA process changes\, drug quality and patient safety\, and choose the right external partner. \nDownload the agenda here: https://ter.li/k46oir \nRegister your place here (and take advantage of group discounts of up to 20% when sending your team of three or more!): https://ter.li/wf4j0
URL:http://www.pharmajournalist.com/event/3rd-mrna-process-development-manufacturing-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240917
DTEND;VALUE=DATE:20240920
DTSTAMP:20260515T154455
CREATED:20240618T121731Z
LAST-MODIFIED:20240618T121731Z
UID:39302-1726531200-1726790399@www.pharmajournalist.com
SUMMARY:2nd ADC Process Development Summit
DESCRIPTION:With cutting-edge strategies and industry insights\, the 2nd ADC Process Development Summit is back with a mission to boost conjugation yield\, optimize purification\, and streamline production to meet regulatory standards all whilst minimizing costs and timelines. \nJoin AstraZeneca\, Bristol Myers Squibb\, Pfizer and a community of industry experts in process development\, conjugation\, purification\, control\, CMC\, and engineering. With a focused discussion on process development challenges\, innovative solutions and practical takeaways\, leave equipped with the technical knowledge and connections to revolutionize your ADC manufacturing process. \nThis Summit is a must attend for everyone looking to increase conjugation yield and enhance TFF\, implement rigorous control strategies for superior drug substance quality\, develop scalable processes to cut unit operations\, accelerate production timelines\, and navigate regulatory landscapes with ease. \nDon’t miss this Summit\, where innovation meets implementation\, ensuring your ADC process development reaches its optimal efficacy and efficiency!
URL:http://www.pharmajournalist.com/event/2nd-adc-process-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240924
DTEND;VALUE=DATE:20240927
DTSTAMP:20260515T154455
CREATED:20240704T165308Z
LAST-MODIFIED:20240704T165357Z
UID:39340-1727136000-1727395199@www.pharmajournalist.com
SUMMARY:6th RAS-Targeted Drug Development Summit
DESCRIPTION:The race to target the remaining RAS mutants continues\, with over 24 clinical and 70 pre-clinical stage programs striving for first- and best-in-class. Now more than ever\, we are witnessing this growing industry make strides to utilize novel modalities and elucidate mechanisms of resistance – making treating patients with RAS mutant cancers beyond NSCLC not just a possibility\, but a reality. \nAs the leading industry-centered forum\, the 6th RAS-Targeted Drug Development Summit 2024 returns to Boston this September and is once again dedicated to every aspect of discovery and development of RAS therapies\, from discovery through to clinical development\, to create effective frontline RAS therapies for cancer and better patient outcomes. \nOver three jam-packed days\, 38+ leading stakeholders will exhibit breakthrough novel data\, latest clinical advancements\, proof-of-concept\, and strategic perspectives\, all armed to improve the standard of care for patients in need. \nThis year’s summit will tackle some of the hottest advances and burning questions in the space\, such as: \n\nTargeting more mutants with RAS(ON) form\, pan-RAS approaches\, and non-canonical targets to combat cancers beyond NSCLC\nDefeating intrinsic or acquired mechanistic resistance and reducing off-target effects to ensure more effective RAS-directed medicines reach the patient\nShowcasing vaccines\, cell therapies\, monovalent and heterobifunctional modalities with improved selectivity and potency to avoid cancer recurrence\nInvestigating valuable combination approaches utilizing inhibitors of up- and downstream high-value targets such as SOS1\, MEK\, RAF\, and ERK\n\nJoin 200+ of your biopharma and academic peers from Early Discovery\, Translational Oncology\, and Clinical Development at the unrivaled end-to-end forum as we foster critical conversations and navigate cutting-edge treatments – empowering the developers of RAS-targeted therapies to make a positive impact on the future of cancer treatment. Join us as we work together to create effective frontline RAS therapies for better patient outcomes. \nTo know more visit: https://ter.li/hosjv6
URL:http://www.pharmajournalist.com/event/6th-ras-targeted-drug-development-summit/
LOCATION:Hilton Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240924
DTEND;VALUE=DATE:20240927
DTSTAMP:20260515T154455
CREATED:20240815T165629Z
LAST-MODIFIED:20240815T165629Z
UID:39596-1727136000-1727395199@www.pharmajournalist.com
SUMMARY:AI for Pharma & Healthcare Summit
DESCRIPTION:Join us for an exploration of accelerating drug development\, streamlining clinical trials and enhancing supply chain efficiency to elevate patient care across the entire value stream at the AI for Pharma & Healthcare Summit! \nImagine a world where drug discovery moves at unprecedented speeds\, clinical trials are streamlined for efficiency\, and regulatory approvals are faster than ever before. Extend that vision to manufacturing and supply chain processes enhanced by machine learning and predictive analytics to ensure that treatment reaches patients not only quicker but also more safely and reliably. This is the future of pharmaceuticals\, where advanced technology enhances every facet of patient care. \nThe transformative potential of AI is reflected in the sector’s financial outlook: the market for AI in Pharma is expected to grow exponentially\, from $3.05 billion to $18.06 billion by 2029. Yet\, amid the excitement\, a healthy dose of scepticism about the “AI Hype” exists. Pharma professionals understand the power of the technology\, but translating potential into reality requires navigating significant challenges. Pharma IQ’s AI for Pharma & Healthcare Summit aims to address these challenges by going beyond the hype\, presenting real-world AI use cases in drug discovery\, clinical trials and supply chain / manufacturing.
URL:http://www.pharmajournalist.com/event/ai-for-pharma-healthcare-summit/
LOCATION:Amsterdam Marriot Hotel\, Stadhouderskade 12\, Amsterdam\, 1054 ES\, Netherlands
ORGANIZER;CN="IQPC Ltd":MAILTO:enquire@iqpc.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240924
DTEND;VALUE=DATE:20240927
DTSTAMP:20260515T154455
CREATED:20240819T231802Z
LAST-MODIFIED:20240819T231802Z
UID:39620-1727136000-1727395199@www.pharmajournalist.com
SUMMARY:8th MASH Drug Development Summit
DESCRIPTION:With Rezdiffra’s approval\, GLPs moving into the space\, and the wave of promising therapeutics in phrase I-III trials\, MASH therapeutics have seen an unprecedented boom in recent months. \nDon’t miss the 8th MASH Drug Development Summit’s industry-specific curated agenda spanning preclinical\, translational\, clinical and regulatory MASH developments designed to help you to overcome barriers in the development and commercialization of MASH therapies. \nWhat are the top program features to look forward to in 2024? \n\nDelve into preclinical anti-fibrotic developments and their impact on ELF and PRO-C3 biomarkers and how to improve fibrosis replication with BMS\, Pfizer and AstraZeneca\nAccelerate your clinical trial design by optimizing cirrhosis\, MASH and fibrosis targets in trials with AstraZeneca and 89Bio\nExamine how GLP-1s can be leveraged in MASH to combat the disease drivers with Altimmune and Seal Rock Therapeutics\nExplore how the regulatory field is shifting and learn how to navigate regulatory approval with Madrigal and AstraZeneca\nLeverage AI techniques and real-world evidence to integrate data\, harmonize predictions and identify future trends for MASH with Merck and AstraZeneca\n\nFind out more here. \nThis is a conversation you won’t want to miss! Discover pricing and registation information here to discover how you can harness competitive intelligence from 3 days of cutting-edge content to supercharge your MASH therapeutic pipeline.
URL:http://www.pharmajournalist.com/event/8th-mash-drug-development-summit/
LOCATION:Boston Logan Airport Hotel\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR